Moteur de recherche d’entreprises européennes

Financement de l’UE (15 M €) : Immuno-Image : imagerie spécifique de la dynamique des cellules immunitaires à l’aide de nouvelles stratégies de traçage Hor 01/10/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Immuno-Image : imagerie spécifique de la dynamique des cellules immunitaires à l’aide de nouvelles stratégies de traçage

Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers. To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions. To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.


Academisch Ziekenhuis Groningen 2 522 958 €
Antaros Medical AB 250 000 €
Bayer AG 0,00 €
Cloudselling B.V. 0,00 €
Commissariat a L Energie Atomique et aux Energies Alternatives 510 000 €
Eberhard Karls Universitaet Tuebingen 1 103 496 €
European Cancer Patient Coalition 0,00 €
F. Hoffmann-LA Roche AG 0,00 €
Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca 514 560 €
Fundacio Privada Institut D'Investigacio Oncologica de Vall-Hebron (Vhio) 433 310 €
Imaginab Inc. 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Lawrencium Legal B.V. 480 000 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
PNO Consultants B.V. 0,00 €
PNO Life Sciences & Health B.V. 376 250 €
Stichting Amsterdam UMC 3 652 347 €
Stichting Lygature 287 500 €
Takeda Development Centre Europe Ltd. 0,00 €
Takeda Pharmaceuticals International AG 0,00 €
The Chancellor Masters and Scholars of the University of Cambridge 702 500 €
Universitaet Muenster 1 836 250 €
Universite Paris-Saclay 0,00 €
VIB VZW 885 000 €
Vrije Universiteit Brussel 1 445 829 €

https://cordis.europa.eu/project/id/831514

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.